Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Smac mimetics (SMs) comprise a class of small molecules that target members of the inhibitor of apoptosis family of pro-survival proteins, whose expression in cancer cells hinders the action of conventional chemotherapeutics. Herein, we describe the activity of SM83, a newly synthesised dimeric SM, in two cancer ascites models: athymic nude mice injected intraperitoneally with IGROV-1 human ovarian carcinoma cells and immunocompetent BALB/c mice injected with murine Meth A sarcoma cells. SM83 rapidly killed ascitic IGROV-1 and Meth A cells in vivo (prolonging mouse survival), but was ineffective against the same cells in vitro. IGROV-1 cells in nude mice were killed within the ascites by a non-apoptotic, tumour necrosis factor (TNF)-dependent mechanism. SM83 administration triggered a rapid inflammatory event characterised by host secretion of TNF, interleukin-1β and interferon-γ. This inflammatory response was associated with the reversion of the phenotype of tumour-associated macrophages from a pro-tumoural M2- to a pro-inflammatory M1-like state. SM83 treatment was also associated with a massive recruitment of neutrophils that, however, was not essential for the antitumoural activity of this compound. In BALB/c mice bearing Meth A ascites, SM83 treatment was in some cases curative, and these mice became resistant to a second injection of cancer cells, suggesting that they had developed an adaptive immune response. Altogether, these results indicate that, in vivo, SM83 modulates the immune system within the tumour microenvironment and, through its pro-inflammatory action, leads cancer cells to die by necrosis with the release of high-mobility group box-1. In conclusion, our work provides evidence that SMs could be more therapeutically active than expected by stimulating the immune system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HMGB1 and RAGE in Inflammation and Cancer
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436 · cited 1×
“engaging receptor for advanced glycation endproducts, TLR4, TLR7 and TLR9 receptors.(44) Furthermore, necrotic cells can prime CD4þ T cells, essential for the development of an adaptive immune response.”
BackgroundIAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis
Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.030 · Cited by 1,218
“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Gyrd-Hansen, M., & Meier, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2889 · Cited by 790
Tumor entrained neutrophils inhibit seeding in the premetastatic lung
Granot, Z., Henke, E., Comen, E. A., King, T. A., Norton, L., & Benezra, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.012 · Cited by 782
Kazama, H., Ricci, J.-E., Herndon, J. M., Hoppe, G., Green, D. R., & Ferguson, T. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.013 · Cited by 627
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
IAPs limit activation of RIP kinases by TNF receptor 1 during development
Moulin, M., Anderton, H., Voss, A. K., Thomas, T., Wong, W. W., Bankovacki, A., Feltham, R., Chau, D., Cook, W. D., Silke, J., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.18 · Cited by 193
Cited by
Mitochondrial control of inflammation
Marchi, S., Guilbaud, E., Tait, S. W. G., Yamazaki, T., & Galluzzi, L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00760-x · Cited by 1,027
Marchetti, P., Fovez, Q., Germain, N., Khamari, R., & Kluza, J. (2020) · The FASEB Journal · doi:10.1096/fj.202000767r · Cited by 322
Small-molecule SMAC mimetics as new cancer therapeutics
Bai, L., Smith, D. C., & Wang, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.05.007 · Cited by 210
“SM83 exerts its antitumor activity by inducing inflammation and immune cell activation and it stimulates the reversion of the tumor-associated macrophages from a pro-tumoral M2- to a pro-inflammatory M1-like state, resulting in secretion by the host of TNFα, IL-1β, and IFNγ, leading to necroptic cell death and release…”
BackgroundInfluentialAsare, P. F., Roscioli, E., Hurtado, P. R., Tran, H. B., Mah, C. Y., & Hodge, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01298 · Cited by 50
Therapeutics Targeting the Core Apoptotic Machinery
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers · doi:10.3390/cancers13112618 · Cited by 26
“Preliminary results from the first‐in‐human study demonstrated manageable safety in combination with chemotherapy, target occupancy and cIAP1 degradation, and preliminary efficacy; this has led to with the FDA granting breakthrough therapy designation for its use in head and neck cancer in 2020 in combina‐ tion with c…”
Background
Metadata
- Authors
- Lecis, D., De Cesare, M., Perego, P., Conti, A., Corna, E., Drago, C., Seneci, P., Walczak, H., Colombo, M. P., Delia, D., & Sangaletti, S.
- Venue
- Cell Death & Disease
- Published
- 2013-11-14
- Volume
- 4
- Issue
- 11
- Pages
- e920-e920
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2061663136
- Cited by
- 50
- References
- 8
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity. https://app.cochat.ai/papers/10.1038/cddis.2013.449
- The paper
- Lecis, D., De Cesare, M., Perego, P., Conti, A., Corna, E., Drago, C., Seneci, P., Walczak, H., Colombo, M. P., Delia, D., & Sangaletti, S. (2013). Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity. Cell Death & Disease. https://doi.org/10.1038/cddis.2013.449
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.